Andrew Gengos - Jan 4, 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Officer
Signature
/s/ Mark Worthington, Attorney-in-fact for Andrew Gengos
Stock symbol
ATHA
Transactions as of
Jan 4, 2024
Transactions value $
-$3,515
Form type
4
Date filed
1/8/2024, 04:42 PM
Previous filing
Jun 9, 2023
Next filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Award $0 +5K +6.25% $0.00 85K Jan 4, 2023 Direct F1, F2
transaction ATHA Common Stock Sale -$3.52K -1.21K -1.42% $2.91 83.8K Jan 5, 2023 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 18, 2023, the reporting person was granted restricted stock units ("RSUs") representing 10,000 shares of Common Stock of the Issuer. The RSUs were scheduled to vest according to the following amended schedule: (1) fifty percent (50%) of the shares subject to the RSU award vest as of the date the the Compensation Committee (the "Committee" determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (2) the remaining fifty percent (50%) of the shares subject to the RSUs shall vest at the completion of the public readout of topline results of the Company's LIFT-AD Phase 2/3 clinical trial, in each case subject to continued service with the Issuer through the applicable vesting date.
F2 On January 4, 2023, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 5,000 RSUs vested and settled on such date.
F3 The reported shares were sold to cover the Issuer's tax withholding obligations in connection with the vesting of RSUs. Such sale was made pursuant to an Issuer-mandated policy and was not subject to discretion.
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Remarks:

Chief Financial Officer and Chief Business Officer